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ABSTRACT
Objectives: To assess the performance of circulating
vascular endothelial growth factor (VEGF) levels as a
tool for diagnosing giant cell arteritis (GCA) in a cohort
of patients referred for assessment of suspected GCA.
Methods: We selected 298 patients recruited to the
multicentre study Temporal Artery Biopsy versus
Ultrasound in diagnosis of suspected GCA (TABUL).
In a random subset of 26 biopsy-proven GCA cases
and 26 controls, serum from weeks 0, 2 and 26 was
analysed for VEGF concentration using ELISA. VEGF
concentration at week 0 was used to generate a
receiver-operating characteristic curve and thereby
identify a cut-off for an abnormal result which was
used to analyse the full patient cohort. Sections of
paraffin-embedded temporal artery were stained by
immunohistochemistry for VEGF.
Results: The mean (95% CI) VEGF concentration at
week 0 was 873 pg/mL (631 to 1110) in 26 patients
versus 476 pg/mL (328 to 625) in 26 controls
(p=0.017). This difference was not observed at any
other time point. The optimal cut-off of 713 pg/mL was
applied to the whole patient cohort (n=298), yielding
sensitivity of 32% and specificity of 85%. This was not
improved by combination with any clinical parameters.
When patients with biopsy-proven GCA were compared
with controls, sensitivity was 58% and specificity
remained 85%. Sections of biopsy from biopsy-
positive GCA showed intense staining in the adventitia
which was not seen in controls.
Conclusions: Serum VEGF concentration predicts
biopsy positivity but is not useful for differentiating
clinical cases of GCA from controls. Further studies
into VEGF as a prognostic marker and therapeutic
target are warranted.
Trial registration number: NCT00974883;
Post-results.
INTRODUCTION
Giant cell arteritis (GCA) is the most common
primary systemic vasculitis1 2 typically presenting
with headache, constitutional symptoms and
visual disturbance.3 Diagnosis is challenging,4
relying on clinical judgement and imperfect yet
potentially invasive tests including temporal
artery biopsy.5 Elevation of inﬂammatory
markers (erythrocyte sedimentation rate (ESR)
and C-reactive protein (CRP)) are non-speciﬁc
and can be misleading.6 Furthermore, perman-
ent visual loss affecting up to 20%7 requires
timely diagnosis. Most patients present to
their general practitioner; therefore, a sero-
logical biomarker that could be tested in
primary care, could aid the diagnosis of GCA
thereby avoiding more invasive, costly and
time-consuming tests.
Pentraxin-3 is a peripheral marker upregu-
lated in GCA, and associated with optic nerve
ischaemia.8 Pentraxins are members of the
acute phase reactant superfamily. Pentraxin-3
is synthesised in response to vascular injury,9
and levels correlate with disease activity in
small-vessel vasculitides.10 11 Therefore, it
holds promise as a potential biomarker in
GCA.
Key messages
What is already known about this subject?
▸ Vascular endothelial growth factor (VEGF),
mainly derived from macrophages and giant
cells, promotes angiogenesis and increased vas-
cular permeability in health and in disease.
▸ Circulating levels of VEGF are increased in
patients with giant cell arteritis (GCA).
What does this study add?
▸ We have shown that levels of circulating VEGF
are significantly higher in patients with newly
diagnosed GCA compared with controls, espe-
cially if their temporal artery histology is posi-
tive, but could not be used to successfully
differentiate between cases and controls.
How might this impact on clinical practice?
▸ There is not enough evidence to use VEGF as a
diagnostic test, either alone or in combination
with clinical features suggesting the diagnosis.
▸ The role of VEGF as a prognostic marker or
potential therapeutic target could be explored.
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Vascular endothelial growth factor (VEGF) promotes
angiogenesis and increased vascular permeability in health
and in disease.12 There are ﬁve variants of which VEGF-A is
the predominant in adults,13 with higher levels in serum
than in plasma.14 In GCA, neoangiogenesis occurs
throughout the vessel wall, correlating with increased
tissue expression of VEGF.15 The main source of VEGF is
CD68 macrophages and giant cells within the vessel
wall,15 16 and this local production of VEGF is mirrored by
raised serum levels of VEGF in patients with GCA com-
pared with controls.8 Furthermore, allelic variants in VEGF
confer different susceptibility to development of GCA17 18
and certain polymorphisms are associated with increased
risk of ischaemic complications.18 19
VEGF may function in GCA either to compensate for
ischaemia in the thickened artery,20 or to drive inﬂamma-
tion by increasing new blood vessels which are the
primary expressers of adhesion molecules involved in
recruitment of inﬂammatory cells.16 Regardless of its role,
VEGF represents an attractive candidate biomarker for
the diagnosis of GCA. We evaluated the performance of
VEGF-A as a diagnostic tool for GCA within a large cohort
study of patients referred with suspected GCA (Temporal
Artery Biopsy vs ULtrasound study (TABUL), HTA 08/
64/01). We also undertook a preliminary investigation of
pentraxin-3 as a candidate diagnostic marker for GCA.
MATERIALS AND METHODS
Study population
We used samples collected during the TABUL study,
n=298 total serum samples, and n=40 total plasma
samples. Written consent was obtained according to the
Declaration of Helsinki (BMJ 1996; 313:1448) and
ethical approval was gained from Berkshire Research
Ethics Committee (09/H0505/132). TABUL recruited
patients referred to secondary care for investigation and
management of suspected GCA. Patients with a previous
diagnosis of GCA or polymyalgia rheumatica, and those
who had received glucocorticoids for longer than 7 days,
were excluded. Among the 298 participants, 202 patients
had a ﬁnal diagnosis of GCA (based on expert consen-
sus using clinical judgement, histology, biochemistry and
imaging), and 96 patients were given a diagnosis other
than GCA (controls). Clinical data were collected during
the study including age, sex, presenting symptoms,
glucocorticoid duration at baseline and laboratory test
results (ESR and CRP). Research bloods were taken at
baseline (week 0) and at week 2 and month 6 of
follow-up. Serum samples were prepared as per standard
protocols and frozen at −80°C within 4 hours. No
samples had been thawed prior to use in this study.
Enzyme-linked immunosorbent assay
Serum samples were analysed in duplicate using a high-
sensitivity ELISA kit (R&D systems, Quantikine Human
VEGF-165 kit, assay range 31.2–2000 pg/mL) according to
the manufacturers’ instructions. Each plate included a
standard curve of known VEGF concentrations, and calcu-
lations were performed using a four-parameter logistical
curve ﬁtting. In a random subset of 26 biopsy-proven GCA
cases and 26 controls, sera from weeks 0, 2 and 26 were
analysed for VEGF concentration using ELISA. VEGF con-
centration at week 0 was used to generate a receiver-
operating characteristic curve and identify a cut-off for
abnormal results, which was used to analyse the full
patient cohort. For pentraxin-3 measurements, plasma
samples were used. Samples from 20 randomly selected
biopsy-proven GCA patients and 20 controls were analysed
in duplicate using a high-sensitivity kit, according to the
manufacturer’s instructions (R&D systems, Quantikine
Human Pentraxin-3 kit, assay range 0.3–20 ng/mL).
Immunohistochemistry
Parafﬁn-embedded temporal artery samples were
obtained from the TABUL study for ﬁve patients; three
had a positive biopsy and two were control patients.
Sections were cut at 4 μm and mounted on adhesive
glass slides for staining. Slides were deparafﬁnised in
xylene and rehydrated through a graded series of 100–
50% ethanol. Endogenous peroxidase activity was
blocked by 3% hydrogen peroxide. Heat-induced
antigen retrieval for VEGF-A was performed by citrate
buffer (10 mM anhydrous citric acid, 0.05% Tween 20,
pH 6.0). Non-speciﬁc reactivity was blocked in buffer
solution containing 3% ﬁltered bovine serum albumin
(BSA). Representative sections from each patient were
incubated with 1:100 dilution of rabbit anti-human
VEGF polyclonal IgG antibody (ABCAM). Negative
control sections were incubated with non-immune rabbit
IgG (R&D Systems). Secondary biotinylated goat anti-
rabbit antibody (Vector Laboratories) was added at
1:250 dilution before incubation with avidin-biotin-
peroxidase (ABC, Vectastain Elite kit, Vector
Laboratories). Staining was developed with DAB sub-
strate kit (Vector Laboratories) and counterstained with
haematoxylin (Vector Laboratories). Images were cap-
tured using a microscope (Zeiss Imager M1) connected
to a camera (Zeiss Axiocam). For general morphological
analysis, serial sections were stained with Mayer’s H&E.
Sample size calculation
For the VEGF subset, sample size was based on previous
analysis21 with mean values in the control group of
362 pg/mL (SD=178 pg/mL) and mean values in the
GCA group of 1145 pg/mL. Therefore, to give an α of
0.01 and a power of 0.9, the required size was 26 per
group. For the pentraxin-3 study, the sample size was
based on Baldini et al8 where pentraxin-3 in controls was
3.97±0.28 ng/mL and in patients with GCA, it was 23.3
±4.06 ng/mL. Therefore, to give an α of 0.01 and a
power of 0.9, the required size was 20 per group.
Subgroup analysis
In 26 cases and 26 controls, we undertook a subanalysis
of glucocorticoid duration, grouping patients according
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to duration of steroid treatment, since the data were
insufﬁcient to allow for overall exposure to be
calculated.
Statistical analyses
Statistical analysis was undertaken in GraphPad Prism
V.6 and SPSS. Unless stated, signiﬁcance was tested with
the Mann-Witney U test for non-normally distributed
data, with Bonferroni correction where appropriate for
multiple comparisons. Receiver-operating characteristic
curves, contingency table analysis, correlation and linear
regression were performed in Prism V.6. Classiﬁcation
and regression tree analysis was performed in SPSS
Statistics V.23 according to its standard protocols, using
an input of VEGF concentration (high/low) and ﬁnal
diagnosis alongside other parameters including ESR,
CRP and individual clinical features.
RESULTS
From 298 available patients in the TABUL cohort (see
ﬁgure 1), a randomly selected subset of 26 biopsy-proven
cases of GCA were compared with 26 control patients
who did not have GCA (Not GCA). These groups had
an identical sex split (62% women each) but the mean
age was slightly higher in the GCA group compared with
controls (76, SD=7.3 vs 66, SD=11.3; p=0.003). The
serum concentration of VEGF was measured at baseline
(week 0), week 2 and week 26 (ﬁgure 2A). The mean
(95% CI) baseline VEGF concentration was 873 pg/mL
(631 to 1110) in GCA compared with 476 pg/mL (328
to 625) in controls (p=0.017). However, this difference
was not observed at any later time point.
Figure 1 Distribution of patients amongst diagnostic groups
in this study. TAB=temporal artery biopsy, US=temporal artery
ultrasound, +=positive result compatible with GCA,
−=negative result.
Figure 2 A. Serum VEGF is raised in patients with biopsy-
proven GCA compared to controls at week 0, but this is not
seen at any other time-point; B. Serum VEGF concentration is
not dependent on duration of glucocorticoid therapy at the
point of serum sampling. Graphs show mean ±SEM,
significance tested with Mann-Whitney U test with Bonferroni
correction; C. The receiver-operating characteristic curve for
VEGF concentration at week 0 generates an optimal cut off of
713pg/ml
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Mean serum VEGF concentration in GCA patients fell
from 873 pg/mL at week 0 to 393 pg/mL at week 2. It
was hypothesised that this rapid decline in VEGF concen-
tration may represent glucocorticoid responsiveness.
Since patients in TABUL had been taking glucocorticoids
for between 0 and 7 days prior to their enrolment, it was
possible that those with a longer duration of glucocortic-
oid therapy would have lower VEGF concentrations. This
was tested with a subanalysis of VEGF concentration
according to duration of glucocorticoid therapy and ﬁnal
diagnosis, but there was no association between gluco-
corticoid exposure and VEGF concentration (ﬁgure 2B).
It was not possible to analyse overall glucocorticoid expos-
ure because the data were insufﬁcient for this purpose.
The data from week 0 were used to ﬁt a receiver-
operating characteristic curve (ﬁgure 2C) which had an
area under the curve of 0.73. The optimal cut-off for an
abnormal result was 713 pg/mL, providing a sensitivity of
65% and speciﬁcity of 88%.
Sera from week 0 were analysed for all available
TABUL patients, whose diagnosis was made by positive
biopsy, positive ultrasound or purely clinical parameters
(ﬁgure 1). VEGF concentration was higher in GCA
(regardless of means of diagnosis) when compared with
control patients but this difference was not signiﬁcant
(597 vs 464 pg/mL, p=0.09, see ﬁgure 3). When patients
were separated into subgroups according to the means
of diagnosis, the VEGF concentration at week 0 was sig-
niﬁcantly higher only for patients with a positive biopsy
(804 vs 464 pg/mL, p=0.001). Diagnoses for control
patients were as follows: 67% non-speciﬁc headache, 1%
temporomandibular dysfunction, 11% cervical spondyl-
osis, 1% granulomatosis with polyangiitis (GPA), 1% other
vasculitis, 19% other diagnosis (mostly acute infections).
We correlated VEGF levels with traditional acute phase
reactants CRP and ESR (ﬁgure 4). There was a moderate
positive correlation for VEGF with CRP (r=0.50; 95% CI
0.40 to 0.58; p<0.001) and a weak positive correlation of
VEGF with ESR (r=0.25; 95% CI 0.14 to 0.26; p<0.001).
When the cut-off of 713 pg/mL was used to dichotom-
ise patient data into normal and abnormal results, the
sensitivity of VEGF concentration at week 0 was 34% and
speciﬁcity was 85%. When patients were subgrouped
according to diagnostic method, speciﬁcity remained
stable but sensitivity fell to 25% for clinical GCA diagno-
ses rising to 58% for biopsy-positive cases (table 1).
Correlation and regression tree analysis undertaken to
determine whether VEGF concentration could be useful
in combination with other parameters including CRP,
ESR, headache, jaw or tongue claudication and sight
loss (temporary or permanent) failed to reveal any com-
bination that improved the diagnostic performance of
the test in this cohort.
It is not known whether VEGF concentration in the
serum reﬂects local VEGF expression in the temporal
artery. Therefore, we used immunohistochemistry to
look for local VEGF expression in biopsy-positive cases
of GCA, compared with control sections from patients
who were not diagnosed with GCA. Representative
images in ﬁgure 5 show that in this small group of
samples, the VEGF staining in biopsy-positive GCA
patients was much stronger than in controls, and was
predominantly in the tunica adventitia, although some
staining was seen in the media.
For analysis of pentraxin-3 as a diagnostic tool, we
used randomly selected patients from TABUL and
Figure 3 VEGF concentration at week 0 is significantly
raised in biopsy-proven GCA (TAB+) but not in Ultrasound-
positive (US+) GCA or in clinical diagnoses of GCA. Graph
shows mean ± 95% CI. Significance tested with Mann-
Whitney U test with Bonferroni correction.
Figure 4 Mild or moderate positive correlation between measurements of A. VEGF and ESR, B. VEGF and CRP at week 0.
4 Goodfellow N, et al. RMD Open 2017;3:e000353. doi:10.1136/rmdopen-2016-000353
RMD Open
compared controls with biopsy-positive GCA patients, on
the basis that this was the group which had a signiﬁcant
difference in VEGF concentration. Groups had similar
proportions of women (60% in GCA group, 55% in
control) but age again was slightly higher in the GCA
group (75, SD 6.3) compared with the controls (69, SD
10.2, p=0.03). Plasma samples were analysed from week
0, 2 and 26. In contrast to the ﬁndings of Baldini et al,
no signiﬁcant difference was observed between patients
with GCA and controls at any of the three time points
tested (ﬁgure 6), therefore this marker was not tested in
any further groups.
DISCUSSION
We hypothesised that VEGF might be a diagnostic
marker in GCA, but the evidence from the current study
was not conclusive evidence, although we have been
able to demonstrate a strong association between
biopsy-positive GCA and elevated serum levels of VEGF.
Serum concentration of VEGF at ﬁrst presentation of
patients with suspected GCA has some predictive power
for a positive temporal artery biopsy. However, it does
not have good diagnostic performance in separating all
cases of GCA, regardless of diagnostic method, from
controls. There are several potential explanations for
this discrepancy. It may be that a positive temporal
artery biopsy reﬂects a more vigorous inﬂammatory
process with increased local and systemic expression of
factors including VEGF; therefore, a higher likelihood
of measuring an abnormal VEGF concentration in the
peripheral blood. Indeed, patients with a positive biopsy
are more likely to have raised inﬂammatory markers,
and more likely to develop visual complications.22 23
Alternatively, it may be that patients with a positive tem-
poral artery biopsy have a more robust diagnosis, there-
fore are more likely to have a high inﬂammatory
response including high VEGF concentrations.
Patients contributing to this study had been receiving
glucocorticoids for up to 7 days at the point of blood col-
lection. Twenty-three per cent controls and 22% GCA
Table 1 VEGF concentration predicts biopsy positivity but is not useful to identify other diagnostic subgroups. Performance
of VEGF expressed as sensitivity and specificity based on data dichotomised by the cut-off of 713 pg/mL, subgrouped
according to method of diagnosis
Parameter All patients Clinically diagnosed GCA Ultrasound-positive GCA Biopsy-proven GCA
Sensitivity 34% 25% 34% 58%
Specificity 85% 85% 85% 85%
GCA, giant cell arteritis; VEGF, vascular endothelial growth factor.
Figure 5 VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. Representative
images of VEGF immunohistochemistry, all taken at 10× magnification. A–C from control patient; A. H&E, B. control IgG,
C. αVEGF; arrow=tunica adventitia. D–F from GCA patient; D. H&E, E. control IgG, F. αVEGF; arrow=internal elastic lamina
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patients had not received any glucocorticoids at baseline
and the remainder had received at least one dose. The
duration of glucocorticoid exposure did not appear to
affect VEGF concentrations in this study. However, it is
possible that VEGF measurements may be more diagnos-
tically accurate if taken prior to any glucocorticoid treat-
ment. For most patients, this would involve testing blood
samples taken at their general practitioners at the point
of initial presentation. This may be a worthwhile future
study.
One limitation of this study is the potential instability
of VEGF after freeze–thawing. All samples used had one
freeze–thaw cycle: they were frozen at acquisition then
defrosted only when used in this study. One paper has
compared samples from four patients which were either
analysed fresh or after various cycles of freeze–thawing,
and found that even after one cycle, the degradation in
serum signal was on average 67% (range 30–90%).24
However, three other studies have failed to observe
any difference in serum VEGF after freeze–thawing up
to 10 times in 30 patients,25 20 patients26 and 9
patients,27 respectively. Therefore, it is not clear whether
the VEGF measured in serum stored at −80°C is an
accurate reﬂection of VEGF concentration at the time of
sampling.
We selected controls for the study on the basis that
they were presenting with a suspected diagnosis of GCA,
but on further investigation, they did not have the condi-
tion. A signiﬁcant limitation to the study is the absence
of samples from other diseases including infection,
malignancy and other inﬂammatory conditions. Further
work could examine the comparative levels across these
diseases; we speculate that the potential lack of differ-
ence between VEGF levels among different inﬂamma-
tory conditions might make it difﬁcult to use as a true
diagnostic marker.
There is debate over the choice of plasma or serum
for the measurement of VEGF concentration. VEGF is
released from platelets on clotting28 and it has been
argued that this would make plasma the sample of
choice for measuring extracellular VEGF.29 This is a
potential limitation given our choice of serum for its
measurement. However, it is not clear whether intracel-
lular or extracellular VEGF is more important in the
inﬂammatory process in GCA. It remains unclear what
contribution clotting would have had on the levels of
VEGF measured or whether this effect was different
between patients and controls. Furthermore, it was not
feasible to measure the VEGF concentration in plasma
as this was collected in far fewer patients in the parent
TABUL study and therefore would have signiﬁcantly
reduced the power of this study. However, we would
suggest that further studies are warranted comparing
VEGF levels in serum and plasma in patients with GCA
and controls.
We tested pentraxin-3 in this cohort, but there was no
difference between biopsy-positive GCA cases and controls.
This was surprising given that Baldini et al reported a
sixfold upregulation of pentraxin-3 in GCA compared with
healthy controls or controls with rheumatoid arthritis.8
Concentration of pentraxin-3 in controls for this study
(3.35 ng/mL) was similar to Baldini et al (3.97 ng/mL)
but concentration in GCA patients (5.48 ng/mL) was sig-
niﬁcantly lower than in Baldini et al (23.3 ng/mL). This
suggests that the groups of GCA patients in the two studies
are different. Baldini et al studied patients with established
GCA for between 0.25 and 125 months, whereas TABUL
studied an inception cohort of new diagnoses. However, if
pentraxin-3 levels increase over time then there ought to
have been an increase over the 6 months of sample collec-
tion in TABUL, which was not seen. Samples for this study
underwent one freeze–thaw cycle, but Baldini et al do not
comment on whether their samples were analysed fresh or
after freeze–thaw. However, there is evidence that freeze–
thawing does not affect measurement of pentraxin-3,30 so
this is probably not the cause of the discrepancy. It would
be informative to study a third population to conﬁrm
whether there is or is not an upregulation in pentraxin-3
measurements in patients with GCA.
A challenge in managing GCA is accurate recognition
or prediction of relapse. Despite early treatment with
high-dose glucocorticoids, 34–79% relapse.31–34 We
cannot predict which patients are likely to relapse; iden-
tiﬁcation of relapse is complicated by presentation with
non-speciﬁc symptoms coupled with normal laboratory
tests in up to 20%.32 It is possible that VEGF may be a
useful marker for the identiﬁcation of relapsing patients,
and this should be tested in future studies.
We report raised tissue expression and systemic con-
centration of VEGF, related to positive temporal artery
biopsy, which in turn predicts more severe disease.
VEGF may be part of a useful healing response to the
vascular inﬂammation and injury, alternatively it may be
driving the inﬂammatory process. If the latter is the
case, then it provides a more speciﬁc therapeutic target
in comparison to the current standard of care. There is
Figure 6 Pentraxin 3 concentrations in the plasma of biopsy-
positive GCA patients and controls are indistinguishable at
weeks 0, 2, and 26. Graph shows mean ± SEM.
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an established role for anti-VEGF therapy in other dis-
eases including neovascularising ophthalmological con-
ditions (such as macular degeneration, proliferative
diabetic retinopathy, retinal vein occlusion35–37) and
cancers including colorectal, breast, ovarian and cer-
vical.38 Therefore, a number of agents are available
which have already been approved for use in humans,
providing possible novel therapeutic options in GCA.
Further studies should focus on delineating the role of
VEGF in GCA to explore its usefulness as a prognostic
and therapeutic target.
In conclusion, we report that serum levels of VEGF, a
molecule with a potential role in the pathogenesis of
GCA, are elevated in patients with newly diagnosed
GCA, but its performance as diagnostic marker is cur-
rently unclear and should be further investigated.
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